Search Search

Fungal Diagnostics for a Healthier Tomorrow

IMMY is a US-based organization with a dedicated focus in mycology. We develop, manufacture, and distribute innovative diagnostic tests and reagents for fungal diseases. Above all, IMMY’s mission is to improve health and save lives for patients all over the world. 

The Problem

Billions at Risk of Serious Illness

The global burden of fungal infections continues to grow throughout the world. From community-acquired to hospital-associated to advanced HIV diseases, fungal infections affect more than 1 billion people globally, accounting for 1.5 million deaths every year. (gaffi.org)

These infections need greater awareness among governments, health agencies, and communities, but more importantly, they need to become better understood and recognizable among those physicians who are providing care to these patients.

The Solution

Comprehensive Fungal Diagnostics Tailored to Every Provider

Accurate diagnosis is key to proper patient care, especially with the continuing rise of improper or unnecessary treatment which can lead to antimicrobial resistance. Providing healthcare professionals rapid, accurate, and affordable diagnostics is lifesaving for many patients.

  • Lateral Flow Assays

    Single Test Format with Rapid Results

    Simple workflows require minimal training or little hands-on time.

    Lateral-Flow-Assays
    Cryptococcal Antigen LFA

    Results in 10 minutes. Highly sensitive & specific. 5 easy steps. 

    Lateral-Flow-Assays
    Aspergillus Galactomannan LFA

    Results in 45 minutes. Highly sensitive & specific. Test more often.

    Lateral-Flow-Assays
    Coccidioides Antibody LFA

    Results in 30 minutes. Reduce send-out testing. Run on all shifts.

  • Enzyme Immunoassays

    Scalable Solutions for Any Lab

    Ideal for both high-volume reference labs and smaller hospital settings.

    EIA Icon-white-1
    Histoplasma Galactomannan EIA

    Results in 2 Hours and 15 Minutes, Reduce send-out testing. 96 Patients per Plate.

    EIA Icon-white-1
    Coccidioides Antibody EIA

    Results in 2 Hours. Highly sensitive and specific. Two 96-well plates. Offers IgG and IgM differentiation.

    EIA Icon-white-1
    Blastomyces Antibody EIA

    Results in 2 Hours. Highly sensitive and specific. Only commercially available diagnostic ELISA kit for the detection of Blastomyces antibody.

    EIA Icon-white-1
    Cryptococcal Antigen EIA

    Results in 2 hours. Most sensitive and specific EIA for the detection of cryptococcal antigen.

  • Polymerase Chain Reaction

    Next-Generation Diagnostics

    Detects fungal pathogens with precision at the molecular level. ‘Ready to use’ reagents – no resuspension/dilution steps required. Compatible with existing laboratory equipment. Enables quick laboratory reporting to support clinical decision-making when time is of the essence.

    PCR Icon-white-1
    Candida auris PCR

    Sensitive to <10 Candida auris genome copies. Proven efficacy in clinical decision making for infection control and patient management.

    PCR Icon-white-1
    Candida species PCR

    Detection of the six main causative species associated with invasive candidiasis (IC): C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, C. dubliniensis, C. krusei.

    PCR Icon-white-1
    Aspergillus PCR

    Differentiation of A. terreus and Aspergillus species. Proven efficacy in the diagnosis of Invasive Aspergillosis (IA).

    PCR Icon-white-1
    Pneumocystis jirovecii PCR

    Human β-globin gene (Endogenous Internal Control). Proven efficacy in the diagnosis of Pneumocystis Pneumonia (PCP).

  • Other Products

    Proven Technologies, Trusted Results

    Time-honored methods for precise detection.

    Asset 2
    Latex Agglutination

    These antibody or antigen detection systems are semi-quantitative tests that detect agglutinating antibodies in the serum of patients with the respective fungal diseases. The LA tests can aid in the diagnosis of the disease.

    Asset 2
    Cleargel™ Immunodiffusion

    In order to overcome the inherently opaque appearance of agarose immunodiffusion plates, IMMY developed Cleargel™. Cleargel™ is a proprietary gelling agent which produces an ultra-clear gel structure for easy visualization of precipitin bands.

    Asset 2
    Complement Fixation

    Fungal antigens and positive controls are used to detect antibodies in patient serum by the complement fixation (CF) procedure. 

    White beakers
    MycoDDR

    MycoDDR is a reliable processing system that facilitates the digestion and decontamination of patient specimens in a controlled process, which is essential for mycobacterium survival and recovery.

Single Test Format with Rapid Results

Simple workflows require minimal training or little hands-on time.

Lateral-Flow-Assays
Cryptococcal Antigen LFA

Results in 10 minutes. Highly sensitive & specific. 5 easy steps. 

Lateral-Flow-Assays
Aspergillus Galactomannan LFA

Results in 45 minutes. Highly sensitive & specific. Test more often.

Lateral-Flow-Assays
Coccidioides Antibody LFA

Results in 30 minutes. Reduce send-out testing. Run on all shifts.

Scalable Solutions for Any Lab

Ideal for both high-volume reference labs and smaller hospital settings.

EIA Icon-white-1
Histoplasma Galactomannan EIA

Results in 2 Hours and 15 Minutes, Reduce send-out testing. 96 Patients per Plate.

EIA Icon-white-1
Coccidioides Antibody EIA

Results in 2 Hours. Highly sensitive and specific. Two 96-well plates. Offers IgG and IgM differentiation.

EIA Icon-white-1
Blastomyces Antibody EIA

Results in 2 Hours. Highly sensitive and specific. Only commercially available diagnostic ELISA kit for the detection of Blastomyces antibody.

EIA Icon-white-1
Cryptococcal Antigen EIA

Results in 2 hours. Most sensitive and specific EIA for the detection of cryptococcal antigen.

Next-Generation Diagnostics

Detects fungal pathogens with precision at the molecular level. ‘Ready to use’ reagents – no resuspension/dilution steps required. Compatible with existing laboratory equipment. Enables quick laboratory reporting to support clinical decision-making when time is of the essence.

PCR Icon-white-1
Candida auris PCR

Sensitive to <10 Candida auris genome copies. Proven efficacy in clinical decision making for infection control and patient management.

PCR Icon-white-1
Candida species PCR

Detection of the six main causative species associated with invasive candidiasis (IC): C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, C. dubliniensis, C. krusei.

PCR Icon-white-1
Aspergillus PCR

Differentiation of A. terreus and Aspergillus species. Proven efficacy in the diagnosis of Invasive Aspergillosis (IA).

PCR Icon-white-1
Pneumocystis jirovecii PCR

Human β-globin gene (Endogenous Internal Control). Proven efficacy in the diagnosis of Pneumocystis Pneumonia (PCP).

Proven Technologies, Trusted Results

Time-honored methods for precise detection.

Asset 2
Latex Agglutination

These antibody or antigen detection systems are semi-quantitative tests that detect agglutinating antibodies in the serum of patients with the respective fungal diseases. The LA tests can aid in the diagnosis of the disease.

Asset 2
Cleargel™ Immunodiffusion

In order to overcome the inherently opaque appearance of agarose immunodiffusion plates, IMMY developed Cleargel™. Cleargel™ is a proprietary gelling agent which produces an ultra-clear gel structure for easy visualization of precipitin bands.

Asset 2
Complement Fixation

Fungal antigens and positive controls are used to detect antibodies in patient serum by the complement fixation (CF) procedure. 

White beakers
MycoDDR

MycoDDR is a reliable processing system that facilitates the digestion and decontamination of patient specimens in a controlled process, which is essential for mycobacterium survival and recovery.

IMMY's tests, including tests for histoplasmosis, cryptococcosis, and coccidioidomycosis, have enabled early and rapid diagnosis. This has provided patients with timely treatment, directly impacting on their survival.
Dr. Lisandra Serra Damasceno, PhD
Federal University of Ceará and Sao José Hospital
The rapid techniques implemented in the laboratory allowed to increase diagnostic sensitivity and reduce the response time in mycological diagnosis, which allowed for the implementation of early targeted treatment.
Vanesa Mabel Eugenia Sosa
Facultad de Ciencias Exactas Químicas y Naturales. Universidad Nacional de Misiones. Hospital Madariaga
At my work institution I have had the opportunity to work with IMMY's products, specifically CrAg LFA, Aspergillus GM LFA, and serology for Histoplasma. All of them have been a very useful tool for a timely diagnosis. In the case of the CrAg LFA, it has been a valuable tool for early detection of Cryptococcosis in HIV patients, increasing survival.

Fungal serology has been very useful for the detection of Histoplasma spp and Paracoccidioides spp, since we are a country endemic for these mycoses.

Without a doubt, IMMY products have been a great ally in my work.
Aleiram Yanit Chaurio Briceño
Instituto Nacional de Higiene Rafael Rangel
The Impact

World-Class Diagnostics

Delivering Innovation and Quality
Service Since 1979

Over

5 million

lives impacted every year by IMMY diagnostics

More than

45 years

of excellence

With

100+

employees dedicated to 1 mission

We are

100%

committed to proving the world’s best fungal diagnostics

Our Reach

Bringing Fungal Diagnostics to a Global Audience

We are continually working to bring diagnostics closer to the patient. Currently, IMMY’s products are available in over 80 countries.

Dive Deeper

Fungal Disease Education

Explore the epidemiology and global impact of often-overlooked fungal diseases. 

Cryptococcus_neoformans_hires-1-1-2
Cryptococcosis

Cryptococcal meningitis is one of the most common opportunistic infections among HIV/AIDS patients, estimating more than 220,000 cases and 181,000 deaths worldwide each year.

histoplasma
Histoplasmosis

Histoplasmosis is the most prevalent endemic mycosis in the United States. Histoplasma capsulatum is a dimorphic fungus found in areas of endemicity around the world, notably in river basins.

Candida auris 1-1
Candida Auris Infections

Over the past decade, Candida auris has emerged as a worldwide public health threat. Since its first isolation in 2009 in Japan, C. auris infections have been reported in over 30 countries.

The Latest Developments

Stay Informed on Mycology Research & Global Health Standards

Access expert resources, industry news, and the latest updates on fungal diseases, diagnostics, and world health guidelines.

who-logo-on-blue-2-1-1
Guidelines
WHO Fungal Priority Pathogens List

The World Health Organization publishes its first ever list of fungal priority pathogens to guide research, development and public health action.

shutterstock_550134823
Publication
Detection and Treatment of Endemic Mycoses

Authors summarize relevant information about epidemiological, clinical, diagnostic, and treatment aspects of the most common endemic mycoses, including blastomycosis, coccidioidomycosis, histoplasmosis, and more. 

ICU patient
Publication
Fungal infections in immunocompromised critically ill patients

In-depth review about the diagnosis, with emphasis on recent advances, and treatment of these invasive fungal infections in the ICU setting.